Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.91
+0.02 (0.25%)
Sep 16, 2026, 4:00 PM EDT - Market closed
← View all transcripts

AGM 2018

Jun 15, 2018

Operator

Good morning. Welcome to the Selecta Biosciences Annual Meeting of Stockholders. I would now like to turn the conference over to Mr. Werner Cautreels. Please go ahead.

Werner Cautreels
President and CEO, Selecta Biosciences

Good morning, ladies and gentlemen. I am Werner Cautreels, President and CEO of Selecta. I would like to welcome you all to our 2018 Annual Meeting of Stockholders. I also want to thank the members of the board and management who are here with us today. I will act as Chairman of this meeting. David Abraham, General Counsel and Chief Compliance Officer, will act as Secretary. Several members of the board are here with us today. In addition, John Lehman, our Chief Financial Officer, Head of Corporate Strategy, and Treasurer, is here with us today, along with Rachel Goldstein, our Vice President and Associate General Counsel, as well as other members of management.

I would also like to introduce Jason Janoff and Peter Catalano of Ernst & Young, the company's independent auditor, who will be available to respond to appropriate questions, as well as Nicole McNeil of Latham & Watkins, outside counsel to the company. The meeting will now officially come to order. I will now turn the meeting over to David Abraham, who will conduct the formal business of the meeting as set forth in the company's notice of annual meeting and proxy statement. David?

David Abraham
General Counsel and Chief Compliance Officer, Selecta Biosciences

Thank you, Werner. We will first run through a few formalities. Only Selecta stockholders of record at the close of business on April 20th, 2018, or holders of a valid proxy are entitled to vote at today's meeting. The Inspector of Election has a complete list of the holders of record of the company's common stock on the record date for the meeting. I have also received an affidavit from the company's mailing agent, Broadridge Financial Solutions, certifying that the delivery of records relating to the company's annual meeting, scheduled for June 15th, 2018, to all stockholders of record as of the record date, was made by means of a mailing which commenced on April 25th. I will file the affidavit with the records of the meeting.

At this time, I'd like to introduce Joseph McClelland, a representative of Broadridge Financial Solutions, whom the board has appointed to serve as the Inspector of Election at today's meeting. Mr. McClelland has signed the customary oath of office to execute his duties with strict impartiality. I have been informed by the Inspector of Election that a majority in voting power of our outstanding common stock is present by remote communication or represented by proxy, and I therefore declare that a quorum exists, and this meeting is duly constituted for the transaction of business. We will now proceed with the formal business of this meeting. The first item of business is the election of Omid Farokhzad , MD, Amir Nashat, PhD, and Amrik Sallan to serve as directors of the company for a term of office expiring at the annual meeting of stockholders to be held in 2021.

The second item of business is the ratification of the audit committee's appointment of Ernst & Young LLP as the independent registered public accounting firm of the company for the year ending December 31st, 2018. Mr. Janov, would you like to make a statement?

Jason Janoff
Representative, Ernst & Young

Yeah. I won't be making a statement today, but I'm available for any questions that you might have.

David Abraham
General Counsel and Chief Compliance Officer, Selecta Biosciences

Thank you. That was the final item of business for today's meeting. The time is now 9:05 A.M. on June 15th, 2018, and the polls are now open for voting on all matters before the meeting. Voting will be by ballot by online ballot. Selecta stockholders of record at the close of business on April 20th, 2018, or holders of a valid proxy who voted online or by telephone prior to this meeting, do not need to vote again by ballot unless they wish to change their vote. If you wish to vote now because you want to change your previously submitted vote, or you have not previously voted, you may do so now by clicking on the Vote Here button found on the web portal. The time is now 9:07 A.M. on June 15th, 2018, and the polls are now closed for voting.

The Inspector of Election will count the votes. Mr. McClelland has provided me with the preliminary report of the Inspector of Election. I will cause the final report of the Inspector of Election to be kept with the company's records of the annual meeting. Based on the report of the Inspector of Election, Omid Farokhzad , MD, Amir Nashat, PhD, and Amrik Sallan have been elected as directors, and the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31st, 2018, has been ratified. The final tally of the votes will be published within four business days in a current report on Form 8-K, to be filed with the Securities and Exchange Commission. With that, I will turn the meeting back over to Werner.

Werner Cautreels
President and CEO, Selecta Biosciences

Thank you, David, and thank you all participants and actively involved people. With that, this meeting is now adjourned.

David Abraham
General Counsel and Chief Compliance Officer, Selecta Biosciences

We will now answer questions from stockholders. Only validated stockholders will be able to ask questions by typing in their question in the Ask a Question box found on the web portal. Before we respond to any questions, please note that these remarks may include forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those discussed. More information about important factors that could cause our actual results to differ materially from our expectations expressed in our forward-looking statements are included in the company's SEC filings, including the company's 2017 annual report on Form 10-K. With that, ladies and gentlemen, this concludes our annual meeting. I want to thank you for attending and for your interest in Selecta.

Operator

This meeting has concluded. Thank you for attending today's presentation. You may now disconnect.